https://www.biopharmawatch.com/news/MOH/molina-healthcare-q3-2026-earnings-release
BiopharmaWatch
en
2026-09-02T13:00:00.000Z
Molina Healthcare Announces Third Quarter 2026 Earnings Release and Conference Call Dates
https://www.biopharmawatch.com/news/HCWB/hcw-biologics-strengthens-patent-hcw9302-alopecia-areata
BiopharmaWatch
en
2026-09-02T13:00:00.000Z
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
https://www.biopharmawatch.com/news/AIM/aim-immunotech-expands-ampligen-patent-protection-long-covid
BiopharmaWatch
en
2026-09-02T12:43:00.000Z
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-longevity-investors-conference-2026
BiopharmaWatch
en
2026-09-02T12:32:00.000Z
Niagen Bioscience to Present at Longevity Investors Conference
https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
https://www.biopharmawatch.com/news/COR/cencora-accelerate-pharmacy-solutions-cell-gene-therapy
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
https://www.biopharmawatch.com/news/CAI/caris-life-sciences-precision-oncology-iaslc-2026
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
https://www.biopharmawatch.com/news/HALO/halozyme-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
Halozyme to Participate at Upcoming Investor Conferences
https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
https://www.biopharmawatch.com/news/VERU/veru-fireside-chat-2026-cantor-conference
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/RNXT/renovorx-presentation-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
https://www.biopharmawatch.com/news/FEED/envue-medical-exhibit-navigation-platform-vizient-exchange
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange
https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-sls009-preclinical-data-aacr-conference
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-cfo-retirement-geoffrey-parker
BiopharmaWatch
en
2026-09-02T12:30:00.000Z
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-fda-orphan-drug-designation-tourette-syndrome
BiopharmaWatch
en
2026-09-02T12:17:00.000Z
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
https://www.biopharmawatch.com/news/ARDT/ardent-health-expansion-specialty-care-ut-tyler
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Ardent Health Marks Expansion of Specialty Care in New UT Tyler School of Medicine
https://www.biopharmawatch.com/news/THC/tenet-participate-wells-fargo-healthcare-conference
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Tenet to Participate in the Wells Fargo Healthcare Conference
https://www.biopharmawatch.com/news/ARGX/benchsci-argenx-agreement-preclinical-drug-discovery
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-cantor-global-healthcare-conference
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-presentations-september-conferences
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
https://www.biopharmawatch.com/news/SRRK/scholar-rock-fda-fast-track-apitegromab-fshd-phase-2
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
https://www.biopharmawatch.com/news/SLN/silence-therapeutics-september-investor-conferences
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Silence Therapeutics to Participate in Three September Investor Conferences
https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Atrium Therapeutics to Participate in Upcoming Investor Conferences
https://www.biopharmawatch.com/news/TRLV/trulieve-september-2026-event-participation
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Trulieve Announces September 2026 Event Participation
https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-2026-cantor-healthcare-conference
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2026-cantor-fitzgerald-conference
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
https://www.biopharmawatch.com/news/XAIR/beyond-air-participate-2026-cantor-healthcare-conference
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-cantor-global-healthcare-conference
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-investor-conferences-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
https://www.biopharmawatch.com/news/IMDX/imdx-participate-lake-street-big10-conference
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
https://www.biopharmawatch.com/news/PRQR/proqr-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
ProQR to Participate in Upcoming Investor Conferences in September 2026
https://www.biopharmawatch.com/news/ALXO/alx-oncology-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
ALX Oncology to Present at Upcoming Investor Conferences in September
https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
https://www.biopharmawatch.com/news/ANNX/annexon-september-investor-conferences-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Annexon to Participate in Upcoming September Investor Conferences
https://www.biopharmawatch.com/news/GERN/geron-present-upcoming-investor-conferences
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Geron to Present at Upcoming Investor Conferences
https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-investor-conferences-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-september-investor-conferences
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
vTv Therapeutics to Participate in September Investor Conferences
https://www.biopharmawatch.com/news/CGON/cg-oncology-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T12:00:00.000Z
CG Oncology to Present at Upcoming Investor Conferences in September
https://www.biopharmawatch.com/news/IMNM/immunome-presents-hc-wainwright-investment-conference
BiopharmaWatch
en
2026-09-02T11:45:00.000Z
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/PLRZ/polyrizon-completes-us-site-contracts-nasarix-allergy-study
BiopharmaWatch
en
2026-09-02T11:32:00.000Z
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
https://www.biopharmawatch.com/news/VSTM/verastem-oncology-september-investor-conferences
BiopharmaWatch
en
2026-09-02T11:30:00.000Z
Verastem Oncology to Participate in Upcoming September Investor Conferences
https://www.biopharmawatch.com/news/ZTS/zoetis-participate-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-09-02T11:30:00.000Z
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/CRON/cronos-spinach-expands-edibles-vapes
BiopharmaWatch
en
2026-09-02T11:30:00.000Z
Cronos’ brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes
https://www.biopharmawatch.com/news/BBIO/bridgebio-new-data-infigratinib-achondroplasia-espe-2026
BiopharmaWatch
en
2026-09-02T11:30:00.000Z
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
https://www.biopharmawatch.com/news/KYNB/kyntra-bio-presentation-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-02T11:30:00.000Z
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-investor-conferences-2026
BiopharmaWatch
en
2026-09-02T11:30:00.000Z
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-investor-conferences-2026
BiopharmaWatch
en
2026-09-02T11:30:00.000Z
Zevra Therapeutics to Present at Upcoming Investor Conferences
https://www.biopharmawatch.com/news/CTSO/cytosorbents-reduces-severe-bleeding-cabg-patients
BiopharmaWatch
en
2026-09-02T11:28:00.000Z
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
https://www.biopharmawatch.com/news/ACB/reject-curaleaf-bid-aurora-cannabis
BiopharmaWatch
en
2026-09-02T11:05:00.000Z
Aurora Cannabis Urges Shareholders to REJECT Curaleaf's Hostile Bid, Warning that it is Inadequate, Undervalues Aurora and Puts Shareholder Value and Future Upside at Risk
https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-agreement-commercial-site-transfer
BiopharmaWatch
en
2026-09-02T11:05:00.000Z
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
https://www.biopharmawatch.com/news/QURE/uniqure-bla-ma-submission-huntingtons-disease
BiopharmaWatch
en
2026-09-02T11:05:00.000Z
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-phase-iii-liver-cancer-study
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
https://www.biopharmawatch.com/news/BLCO/bausch-lomb-envista-aspire-research
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
https://www.biopharmawatch.com/news/NVCR/novocure-upcoming-investor-events
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Novocure Announces Upcoming Investor Events
https://www.biopharmawatch.com/news/UTHR/fda-acceptance-snda-nebulized-tyvaso-ipf
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
https://www.biopharmawatch.com/news/NVS/alteogen-novartis-license-agreement-hybrozyme
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-cantor-2026-healthcare-conference
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-strategic-reorganization-solid-tumors
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
https://www.biopharmawatch.com/news/MDWD/mediwound-presents-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-participate-september-2026-conferences
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Cardiff Oncology to Participate in September 2026 Conferences
https://www.biopharmawatch.com/news/EYPT/eyepoint-participation-investor-conferences-scientific-meeting
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
https://www.biopharmawatch.com/news/FTRE/fortrea-acquires-early-phase-services-worldwide
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
https://www.biopharmawatch.com/news/IRD/opus-genetics-opgx-best1-clinical-data-presentation
BiopharmaWatch
en
2026-09-02T11:00:00.000Z
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
https://www.biopharmawatch.com/news/MRK/merck-participate-wells-fargo-healthcare-conference
BiopharmaWatch
en
2026-09-02T10:45:00.000Z
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
https://www.biopharmawatch.com/news/IMUX/immunic-virtual-rd-day-relapsing-ms-september-2026
BiopharmaWatch
en
2026-09-02T10:30:00.000Z
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
https://www.biopharmawatch.com/news/CMPS/compass-pathways-fierce-50-honoree-2026
BiopharmaWatch
en
2026-09-02T10:30:00.000Z
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
https://www.biopharmawatch.com/news/IMUX/immunic-virtual-rd-day-relapsing-ms-september-2026
BiopharmaWatch
en
2026-09-02T10:30:00.000Z
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
https://www.biopharmawatch.com/news/MDT/cornerstone-robotics-medtronic-partnership-robotic-surgery
BiopharmaWatch
en
2026-09-02T07:36:00.000Z
Cornerstone Robotics gibt strategische Partnerschaft mit Medtronic bekannt, um den weltweiten Zugang zu robotergestützter Chirurgie zu erweitern
https://www.biopharmawatch.com/news/EVO/evotec-plectonic-collaboration-tcell-solid-tumors
BiopharmaWatch
en
2026-09-02T06:04:00.000Z
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
https://www.biopharmawatch.com/news/IPHA/innate-pharma-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-02T05:00:00.000Z
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/MDT/cornerstone-robotics-medtronic-strategic-alliance
BiopharmaWatch
en
2026-09-02T04:48:00.000Z
Cornerstone Robotics anuncia una alianza estratégica con Medtronic
https://www.biopharmawatch.com/news/MDT/cornerstone-robotics-medtronic-partnership-robotic-surgery
BiopharmaWatch
en
2026-09-02T02:45:00.000Z
Cornerstone Robotics ogłasza strategiczne partnerstwo z Medtronic mające na celu zwiększenie dostępu do chirurgii robotycznej na świecie
https://www.biopharmawatch.com/news/NUTX/nutex-health-data-breach-investigation
BiopharmaWatch
en
2026-09-02T01:56:00.000Z
Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data
https://www.biopharmawatch.com/news/ZEPP/zepp-health-q2-2026-financial-results
BiopharmaWatch
en
2026-09-02T01:00:00.000Z
Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results
https://www.biopharmawatch.com/news/TLX/telix-completes-enrollment-phase-3-bipass-study
BiopharmaWatch
en
2026-09-01T22:18:00.000Z
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
https://www.biopharmawatch.com/news/PNTG/pennant-group-2026-jefferies-healthcare-conference
BiopharmaWatch
en
2026-09-01T22:07:00.000Z
Pennant Group to Participate in the 2026 Jefferies Healthcare Services Conference
https://www.biopharmawatch.com/news/HWH/hwh-international-executive-leadership-transition
BiopharmaWatch
en
2026-09-01T21:27:00.000Z
HWH International Inc. Announces Executive Leadership Transition
https://www.biopharmawatch.com/news/NPCE/neuropace-participate-2026-cantor-healthcare-conference
BiopharmaWatch
en
2026-09-01T21:01:00.000Z
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/ATYR/atyr-pharma-update-fda-response-phase-3-study-efzofitimod
BiopharmaWatch
en
2026-09-01T20:36:00.000Z
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
https://www.biopharmawatch.com/news/IBIO/ibio-participate-wells-fargo-healthcare-conference-2026
BiopharmaWatch
en
2026-09-01T20:30:00.000Z
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-acquires-nautilus-pharmacy-assets
BiopharmaWatch
en
2026-09-01T20:30:00.000Z
Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy
https://www.biopharmawatch.com/news/BRVE/braveheart-bio-cantor-global-healthcare-conference
BiopharmaWatch
en
2026-09-01T20:30:00.000Z
Braveheart Bio to Participate in Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/CLLS/cellectis-participation-upcoming-investor-conferences
BiopharmaWatch
en
2026-09-01T20:30:00.000Z
Cellectis Announces Participation in Upcoming Investor Conferences
https://www.biopharmawatch.com/news/PACS/pacs-group-acquires-32-facilities-florida
BiopharmaWatch
en
2026-09-01T20:15:00.000Z
PACS Group to Acquire Operations of 32 Facilities Across Florida and Closes on Additional Previously Announced Eduro Facilities
https://www.biopharmawatch.com/news/ANAB/anaptys-hc-wainwright-investment-conference-2026
BiopharmaWatch
en
2026-09-01T20:15:00.000Z
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/RARE/ultragenyx-genglycos-dtx401-trial-results
BiopharmaWatch
en
2026-09-01T20:05:14.000Z
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
https://www.biopharmawatch.com/news/MYO/myomo-presents-hc-wainwright-investment-conference
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-investor-conferences-september
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
https://www.biopharmawatch.com/news/SI/shoulder-innovations-morgan-stanley-conference-2026
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference
https://www.biopharmawatch.com/news/INO/inovio-participate-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
INOVIO to Participate in Upcoming Investor Conferences
https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/BBOT/bbot-participate-investor-healthcare-conferences
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
BBOT to Participate in Upcoming Investor Healthcare Conferences
https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-investor-conferences-2026
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
https://www.biopharmawatch.com/news/SANA/sana-biotechnology-september-2026-investor-conferences
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Sana Biotechnology to Present at September 2026 Investor Conferences
https://www.biopharmawatch.com/news/SGHT/sight-sciences-morgan-stanley-conference-2026
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-morgan-stanley-conference-2026
BiopharmaWatch
en
2026-09-01T20:05:00.000Z
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/CLGN/collplant-reverse-share-split-september-2026
BiopharmaWatch
en
2026-09-01T20:01:00.000Z
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
https://www.biopharmawatch.com/news/ARVN/arvinas-inducement-grant-nasdaq-rule-5635c4
BiopharmaWatch
en
2026-09-01T20:01:00.000Z
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
https://www.biopharmawatch.com/news/RMT/royce-micro-cap-trust-third-quarter-distribution
BiopharmaWatch
en
2026-09-01T19:33:06.575Z
Royce Micro-Cap Trust, Inc. (NYSE-RMT) declares Third Quarter Common Stock Distribution of $0.23 Per Share
https://www.biopharmawatch.com/news/SBC/sbc-medical-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-01T17:35:00.000Z
SBC Medical to Participate in Several Upcoming Investor Conferences in September 2026
https://www.biopharmawatch.com/news/KYTX/kyverna-miv-cel-safety-profile-update
BiopharmaWatch
en
2026-09-01T17:00:00.000Z
Company Statement on Miv-cel's Favorable Safety Profile
https://www.biopharmawatch.com/news/ONC/beone-medicines-partnership-us-government-cancer-therapy
BiopharmaWatch
en
2026-09-01T16:46:00.000Z
شركة BeOne Medicines تعلن عن إبرام اتفاقية طوعية مع الحكومة الأمريكية لتعزيز وتوسيع إمكانية الحصول على علاجات السرطان المُبتكرة
https://www.biopharmawatch.com/news/ONC/beone-medicines-us-agreement-cancer-drugs
BiopharmaWatch
en
2026-09-01T16:46:00.000Z
BeOne Medicines anuncia acordo voluntário com o governo dos EUA para expandir o acesso a medicamentos inovadores contra o câncer
https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-drugs
BiopharmaWatch
en
2026-09-01T16:46:00.000Z
BeOne Medicines anuncia un acuerdo voluntario con el Gobierno de EE. UU. para ampliar el acceso a medicamentos innovadores contra el cáncer
https://www.biopharmawatch.com/news/ONC/beone-medicines-us-agreement-oncology-drugs
BiopharmaWatch
en
2026-09-01T16:45:00.000Z
Riassunto: BeOne Medicines annuncia un accordo volontario con l'Amministrazione degli Stati Uniti per ampliare l'accesso a farmaci oncologici innovativi
https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-drugs
BiopharmaWatch
en
2026-09-01T16:45:00.000Z
BeOne Medicines gibt freiwillige Vereinbarung mit der US-Regierung bekannt, um den Zugang zu innovativen Krebsmedikamenten zu erweitern
https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-drugs
BiopharmaWatch
en
2026-09-01T16:45:00.000Z
Samenvatting: BeOne Medicines kondigt vrijwillige overeenkomst met Amerikaanse overheid aan om toegang tot innovatieve kankermedicijnen te vergroten
https://www.biopharmawatch.com/news/AZN/oral-pcsk9-inhibitor-market-growth-2026
BiopharmaWatch
en
2026-09-01T14:31:00.000Z
The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight
https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-zihiera
BiopharmaWatch
en
2026-09-01T14:21:00.000Z
BeOne Medicines تعلن عن بيانات جديدة من المرحلة الثالثة حول معدلات البقاء على قيد الحياة، تعزّز الفوائد العلاجية للأنظمة الدوائية المحتوية على ZIIHERA لدى مرضى سرطان المعدة والمريء الإيجابي لمستقبل HER2+ في خط العلاج الأول
https://www.biopharmawatch.com/news/LLY/lilly-morgan-stanley-healthcare-conference-2026
BiopharmaWatch
en
2026-09-01T14:00:00.000Z
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-international-expansion
BiopharmaWatch
en
2026-09-01T13:30:00.000Z
Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
https://www.biopharmawatch.com/news/PHGE/biomx-changes-name-to-tessera-defense
BiopharmaWatch
en
2026-09-01T13:25:00.000Z
BiomX Inc. to Become Tessera Defense and Homeland Security Inc.
https://www.biopharmawatch.com/news/LEXX/lexaria-receives-2-6-million-tax-rebate
BiopharmaWatch
en
2026-09-01T13:21:00.000Z
Lexaria Receives USD$2.6 Million Tax Rebate Payment
https://www.biopharmawatch.com/news/BMRN/biomarin-acquires-alesta-therapeutics
BiopharmaWatch
en
2026-09-01T13:05:00.000Z
BioMarin Announces Close of the Alesta Therapeutics Acquisition
https://www.biopharmawatch.com/news/SYK/stryker-fda-authorized-surgical-application-apple-vision-pro
BiopharmaWatch
en
2026-09-01T13:05:00.000Z
Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
https://www.biopharmawatch.com/news/VRTX/vertex-acquisition-crinetics-expansion-leadership
BiopharmaWatch
en
2026-09-01T13:03:00.000Z
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
https://www.biopharmawatch.com/news/BLLN/billiontoone-launches-northstar-origin-liquid-biopsy-test
BiopharmaWatch
en
2026-09-01T13:00:00.000Z
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
https://www.biopharmawatch.com/news/NXG/nxg-nextgen-infrastructure-income-fund-distributions
BiopharmaWatch
en
2026-09-01T12:40:52.842Z
NXG NextGen Infrastructure Income Fund (NYSE: NXG) Announces Distributions
https://www.biopharmawatch.com/news/SRV/nxg-cushing-midstream-energy-fund-distributions
BiopharmaWatch
en
2026-09-01T12:40:35.420Z
NXG Cushing® Midstream Energy Fund (NYSE: SRV) Announces Distributions
https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-98-percent-accuracy-study
BiopharmaWatch
en
2026-09-01T12:31:00.000Z
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-wells-fargo-conference-2026
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
https://www.biopharmawatch.com/news/DXCM/dexcom-upcoming-conference-presentation
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Dexcom Announces Upcoming Conference Presentation
https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/SDGR/schrodinger-presents-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
https://www.biopharmawatch.com/news/FBLG/fibrobiologics-new-patent-degenerative-disc-disease
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
https://www.biopharmawatch.com/news/AMIX/autonomix-medical-abstracts-cirse-2026
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
https://www.biopharmawatch.com/news/MDAI/spectral-ai-presentation-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Spectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-september-october-2026-conference-schedule
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Conexeu Sciences Sets September and October 2026 Conference Schedule
https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-appoints-dr-will-charlton-cmo
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-private-placement-15-million
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules
https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-wells-fargo-conference-2026
BiopharmaWatch
en
2026-09-01T12:30:00.000Z
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
https://www.biopharmawatch.com/news/BMRA/biomerica-fiscal-2026-financial-results
BiopharmaWatch
en
2026-09-01T12:19:00.000Z
Biomerica Reports Fiscal 2026 Year-End Financial Results
https://www.biopharmawatch.com/news/MDT/cornerstone-robotics-medtronic-partnership-robotic-surgery
BiopharmaWatch
en
2026-09-01T12:17:00.000Z
Cornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted Surgery
https://www.biopharmawatch.com/news/APPT/apptly-koning-partnership-breast-imaging
BiopharmaWatch
en
2026-09-01T12:06:14.748Z
Apptly and Koning Announce Strategic Partnership to Expand Patient Access to Non-Compression 3D Breast Imaging
https://www.biopharmawatch.com/news/BFLY/butterfly-network-merge-labs-partnership-bci
BiopharmaWatch
en
2026-09-01T12:05:00.000Z
Merge Labs and Butterfly Network Partner to Advance Ultrasound-Based Brain-Computer Interfaces
https://www.biopharmawatch.com/news/GH/guardant-health-shield-blood-test-carelon-coverage
BiopharmaWatch
en
2026-09-01T12:05:00.000Z
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
https://www.biopharmawatch.com/news/VIVS/vivosim-labs-rat-liver-model-namkind-platform
BiopharmaWatch
en
2026-09-01T12:05:00.000Z
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
https://www.biopharmawatch.com/news/BHC/bausch-health-solta-medical-fraxel-ftx-australia
BiopharmaWatch
en
2026-09-01T12:01:00.000Z
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
https://www.biopharmawatch.com/news/ABSI/absci-participate-upcoming-investor-conferences
BiopharmaWatch
en
2026-09-01T12:00:31.000Z
Absci to Participate in Upcoming Investor Conferences
https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-advances-mira-55-ind
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
https://www.biopharmawatch.com/news/INCY/incyte-to-present-at-investor-conferences
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Incyte to Present at Upcoming Investor Conferences
https://www.biopharmawatch.com/news/GNPX/andelyn-biosciences-genprex-diabetes-gene-therapy
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-investor-conferences-2026
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Scribe Therapeutics to Participate in Upcoming Investor Conferences
https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-investor-meetings-wells-fargo-2026
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
https://www.biopharmawatch.com/news/VOR/vor-bio-participate-september-conferences
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Vor Bio To Participate in Upcoming September Conferences
https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Dianthus Therapeutics to Participate in Three Investor Conferences During September
https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-september-investor-conferences
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-wells-fargo-conference-2026
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-wells-fargo-conference
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
https://www.biopharmawatch.com/news/PMN/promis-neurosciences-september-conferences-2026
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
https://www.biopharmawatch.com/news/CABA/cabaletta-bio-investor-conferences-2026
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
Cabaletta Bio to Participate in Upcoming Investor Conferences
https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-advancement
BiopharmaWatch
en
2026-09-01T12:00:00.000Z
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-cyfendus-anthrax-vaccine-contract
BiopharmaWatch
en
2026-09-01T11:55:00.000Z
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
https://www.biopharmawatch.com/news/KALA/kala-virotek-exclusive-distribution-partnership
BiopharmaWatch
en
2026-09-01T11:45:00.000Z
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
https://www.biopharmawatch.com/news/CMND/clearmind-phase-iia-trial-cmnd-100-aud
BiopharmaWatch
en
2026-09-01T11:37:00.000Z
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
https://www.biopharmawatch.com/news/DCGO/docgo-participation-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-09-01T11:35:00.000Z
DocGo Announces Upcoming Participation at Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/BIIB/stoke-biogen-eec-zorevunersen-dravet-syndrome
BiopharmaWatch
en
2026-09-01T11:30:36.000Z
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-september-investor-conferences
BiopharmaWatch
en
2026-09-01T11:30:00.000Z
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-immunotherapy-colorectal-cancer
BiopharmaWatch
en
2026-09-01T11:30:00.000Z
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
https://www.biopharmawatch.com/news/NRC/brain-aneurysm-awareness-month-2026
BiopharmaWatch
en
2026-09-01T11:30:00.000Z
Brain Aneurysm Foundation Marks Brain Aneurysm Awareness Month with National Research, Education and Community Initiatives
https://www.biopharmawatch.com/news/STOK/stoke-biogen-eec-zorevunersen-dravet-syndrome
BiopharmaWatch
en
2026-09-01T11:30:00.000Z
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
https://www.biopharmawatch.com/news/ALMS/alumis-envudeucitinib-phase-2b-trial-results
BiopharmaWatch
en
2026-09-01T11:30:00.000Z
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-breast-cancer-trial-expansion
BiopharmaWatch
en
2026-09-01T11:15:00.000Z
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
https://www.biopharmawatch.com/news/KURA/kura-oncology-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-01T11:15:00.000Z
Kura Oncology to Participate in Three Investor Conferences in September
https://www.biopharmawatch.com/news/USNA/usana-ceo-kevin-guest-service-others
BiopharmaWatch
en
2026-09-01T11:06:00.000Z
USANA CEO Kevin Guest Calls on People to Find a Way to Serve Others, Then Act
https://www.biopharmawatch.com/news/NEO/neogenomics-participate-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-09-01T11:05:00.000Z
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-01T11:05:00.000Z
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/OCGN/ocugen-phase-3-trial-ocu410-geographic-atrophy
BiopharmaWatch
en
2026-09-01T11:02:00.000Z
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-marc-elia-ceo-vyd2311-studies-update
BiopharmaWatch
en
2026-09-01T11:01:00.000Z
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-scientific-conferences-2026
BiopharmaWatch
en
2026-09-01T11:00:38.000Z
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-eric-foster-appointment
BiopharmaWatch
en
2026-09-01T11:00:26.000Z
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-september-investor-conferences
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Enanta Pharmaceuticals to Participate in September Investor Conferences
https://www.biopharmawatch.com/news/AZN/astrazeneca-global-license-agreement-zegfrov
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
https://www.biopharmawatch.com/news/ACET/adicet-bio-prula-cel-study-completion
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
https://www.biopharmawatch.com/news/UTHR/united-therapeutics-investor-conferences-2026
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
https://www.biopharmawatch.com/news/HROW/harrow-participate-investor-conferences-september-2026
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Harrow to Participate in Three Investor Conferences in September
https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-3-verekitug-asthma-crsnp
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-phase-1-2-solara-trial-bh-30643
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-presentations-european-congresses
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-morgan-stanley-conference-2026
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/AXGN/axogen-participate-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-hc-wainwright-conference-2026
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-participate-2026-cantor-conference
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-participate-cantor-healthcare-conference
BiopharmaWatch
en
2026-09-01T11:00:00.000Z
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/BLCO/women-dont-recognize-dry-eye-perimenopause-menopause
BiopharmaWatch
en
2026-09-01T10:58:00.000Z
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
https://www.biopharmawatch.com/news/WGS/genedx-ceo-katherine-stueland-fierce-50-honoree
BiopharmaWatch
en
2026-09-01T10:55:00.000Z
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
https://www.biopharmawatch.com/news/MMED/minimed-strong-start-fiscal-year-2027-growth-acceleration
BiopharmaWatch
en
2026-09-01T10:45:00.000Z
MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
https://www.biopharmawatch.com/news/MDT/medtronic-q1-fiscal-2027-results-guidance
BiopharmaWatch
en
2026-09-01T10:45:00.000Z
Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
https://www.biopharmawatch.com/news/ENOV/ecential-robotics-binding-offer-enovis
BiopharmaWatch
en
2026-09-01T10:45:00.000Z
eCential Robotics Announces Binding Offer from Enovis
https://www.biopharmawatch.com/news/MDT/medtronic-partnership-cornerstone-robotics-surgery
BiopharmaWatch
en
2026-09-01T10:40:00.000Z
Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
https://www.biopharmawatch.com/news/RFL/greater-boston-urology-expansion
BiopharmaWatch
en
2026-09-01T10:39:00.000Z
Dr. Akash Sharma and Dr. Rafael Tua-Caraccia Join Greater Boston Urology, an Affiliate of U.S. Urology Partners
https://www.biopharmawatch.com/news/CMPS/compass-pathways-2026-cantor-conference
BiopharmaWatch
en
2026-09-01T10:30:00.000Z
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
https://www.biopharmawatch.com/news/MDT/medtronic-invests-pi-cardia-accelerate-tavr-innovation
BiopharmaWatch
en
2026-09-01T10:30:00.000Z
Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
https://www.biopharmawatch.com/news/TECH/bio-techne-science-based-targets-validation-climate-goals
BiopharmaWatch
en
2026-09-01T10:30:00.000Z
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
https://www.biopharmawatch.com/news/IMUX/immunic-appoints-chitrang-dave-cddo
BiopharmaWatch
en
2026-09-01T10:30:00.000Z
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
https://www.biopharmawatch.com/news/ENOV/enovis-acquires-ecential-robotics-surgical-innovation
BiopharmaWatch
en
2026-09-01T10:30:00.000Z
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
https://www.biopharmawatch.com/news/NUMIF/numinus-wellness-corporate-update-september-2026
BiopharmaWatch
en
2026-09-01T10:04:46.602Z
Numinus Wellness Inc. Provides Corporate Update
https://www.biopharmawatch.com/news/HEAL/holy-crap-amazon-us-rollout-protein-innovations
BiopharmaWatch
en
2026-09-01T10:04:35.572Z
Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations
https://www.biopharmawatch.com/news/ONC/beone-medicines-morgan-stanley-conference-2026
BiopharmaWatch
en
2026-09-01T10:00:00.000Z
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/NTRA/natera-signatera-mrd-assessment-lymphoma-validation
BiopharmaWatch
en
2026-09-01T10:00:00.000Z
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-presentation-wells-fargo-conference
BiopharmaWatch
en
2026-09-01T10:00:00.000Z
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-london-investor-rd-day-september-2026
BiopharmaWatch
en
2026-09-01T10:00:00.000Z
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-business-development-strategy
BiopharmaWatch
en
2026-09-01T09:01:00.000Z
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
https://www.biopharmawatch.com/news/RENX/renx-microtec-mill-delivery-growing-media-florida
BiopharmaWatch
en
2026-09-01T08:30:00.000Z
RenX Takes Delivery of its Microtec Mill, a Step Toward Growing Media Made in Florida
https://www.biopharmawatch.com/news/VBIO/valion-bio-management-board-changes
BiopharmaWatch
en
2026-09-01T08:00:00.000Z
Valion Bio Announces Changes to Management and Board of Directors
https://www.biopharmawatch.com/news/TELO/3rd-international-conference-womens-health-breast-cancer
BiopharmaWatch
en
2026-09-01T07:45:49.000Z
3rd International Conference on Women’s Health and Breast Cancer
https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals
BiopharmaWatch
en
2026-09-01T07:16:19.006Z
FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions
https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch
BiopharmaWatch
en
2026-09-01T07:15:55.843Z
Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks
https://www.biopharmawatch.com/blog/fda-calendar-september-2026
BiopharmaWatch
en
2026-09-01T07:15:28.766Z
FDA Calendar September 2026: A Critical Look at Upcoming Approvals
https://www.biopharmawatch.com/news/MRNA/moderna-upcoming-conferences-september-2026
BiopharmaWatch
en
2026-09-01T07:00:00.000Z
Moderna to Present at Upcoming Conferences in September 2026
https://www.biopharmawatch.com/news/NVS/novartis-remibrutinib-phase-iii-results
BiopharmaWatch
en
2026-09-01T05:15:00.000Z
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
https://www.biopharmawatch.com/news/YDES/yd-bio-revenue-growth-2026
BiopharmaWatch
en
2026-09-01T03:46:48.000Z
YD Bio 公布截至2026年6月30日止六個月財務業績
https://www.biopharmawatch.com/news/PMVP/pmv-pharma-pricing-50-million-public-offering
BiopharmaWatch
en
2026-09-01T03:03:00.000Z
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
https://www.biopharmawatch.com/news/ADMA/berger-montague-investigates-adma-biologics-board
BiopharmaWatch
en
2026-09-01T02:39:17.085Z
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
https://www.biopharmawatch.com/news/VCRE/vicore-pharma-healthcare-conferences-2026
BiopharmaWatch
en
2026-09-01T02:20:00.000Z
Vicore Pharma to Participate in Upcoming Healthcare Conferences
https://www.biopharmawatch.com/news/BETR/betterlife-pharma-us100-million-offering
BiopharmaWatch
en
2026-09-01T00:48:10.980Z
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
https://www.biopharmawatch.com/news/ROVA/altrova-health-q3-fiscal-2026-results
BiopharmaWatch
en
2026-09-01T00:42:34.571Z
Altrova Health Reports Third Quarter Fiscal 2026 Financial Results
https://www.biopharmawatch.com/news/DTR/diagnostear-technologies-private-placement-units
BiopharmaWatch
en
2026-09-01T00:42:23.565Z
DiagnosTear Technologies Inc. Announces Private Placement of Units
https://www.biopharmawatch.com/news/CHER/cheelcare-fiscal-2026-results-curio-update
BiopharmaWatch
en
2026-09-01T00:42:10.675Z
Cheelcare Announces Fourth Quarter and Fiscal 2026 Financial Results and Provides Curio Update
https://www.biopharmawatch.com/news/TLT/theralase-releases-q2-2026-financial-statements
BiopharmaWatch
en
2026-09-01T00:40:37.538Z
Theralase(R) Releases Q2 2026 Financial Statements
https://www.biopharmawatch.com/news/SHRX/sharp-therapeutics-h1-2026-results-update
BiopharmaWatch
en
2026-09-01T00:40:24.537Z
Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update
https://www.biopharmawatch.com/news/DTC/defence-therapeutics-expands-radiopharmaceutical-strategy
BiopharmaWatch
en
2026-09-01T00:40:11.365Z
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
https://www.biopharmawatch.com/news/MRNA/moderna-upsized-convertible-senior-notes-offering
BiopharmaWatch
en
2026-09-01T00:36:28.377Z
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-minuteclinic-offering-updated-flu-vaccines
BiopharmaWatch
en
2026-09-01T00:34:57.682Z
CVS Pharmacy(R) and MinuteClinic(R) Now Offering Updated Flu Vaccines Nationwide
https://www.biopharmawatch.com/news/LOBE/lobe-sciences-upsizes-private-placement
BiopharmaWatch
en
2026-09-01T00:33:57.459Z
Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-fda-approval-mimrylo-polycythemia-vera
BiopharmaWatch
en
2026-09-01T00:33:34.891Z
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
https://www.biopharmawatch.com/news/LOBE/lobe-sciences-new-cfo-appointment
BiopharmaWatch
en
2026-09-01T00:33:21.802Z
Lobe Sciences Expands Leadership Team with New CFO Appointment
https://www.biopharmawatch.com/news/TNON/tenon-medical-private-placement-offering
BiopharmaWatch
en
2026-09-01T00:33:09.752Z
Tenon Medical Announces Pricing of $3M Private Placement Offering
https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-breast-cancer-trial-expansion
BiopharmaWatch
en
2026-09-01T00:00:00.000Z
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ...
https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-preclinical-data
BiopharmaWatch
en
2026-09-01T00:00:00.000Z
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
https://www.biopharmawatch.com/news/BIIB/canadas-drug-agency-recommends-leqembi-reimbursement
BiopharmaWatch
en
2026-08-31T23:30:47.000Z
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
https://www.biopharmawatch.com/news/TLX/telix-appoints-david-gill-chair
BiopharmaWatch
en
2026-08-31T22:21:00.000Z
Telix Appoints David Gill as Chair
https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-soho-2026-presentations
BiopharmaWatch
en
2026-08-31T22:05:00.000Z
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-epetraborole-polycythemia-vera-soho-2026
BiopharmaWatch
en
2026-08-31T22:00:00.000Z
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
https://www.biopharmawatch.com/news/IRON/disc-medicine-soho-2026-presentations
BiopharmaWatch
en
2026-08-31T22:00:00.000Z
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
https://www.biopharmawatch.com/news/YDES/yd-bio-limited-financial-results-june-2026
BiopharmaWatch
en
2026-08-31T22:00:00.000Z
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-oversubscribed-public-offering
BiopharmaWatch
en
2026-08-31T21:58:00.000Z
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
https://www.biopharmawatch.com/news/ACET/adicet-bio-inducement-grant-nasdaq-rule-5635
BiopharmaWatch
en
2026-08-31T21:39:00.000Z
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
https://www.biopharmawatch.com/news/JNJ/johnson-johnson-investor-conference-call-q3-results
BiopharmaWatch
en
2026-08-31T21:08:00.000Z
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-morgan-stanley-conference-2023
BiopharmaWatch
en
2026-08-31T20:30:00.000Z
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/ZURA/zura-bio-participate-cantor-healthcare-conference
BiopharmaWatch
en
2026-08-31T20:30:00.000Z
Zura Bio to Participate in the Cantor Global Healthcare Conference
https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-josh-hexter-ceo-rami-aviram-cfo
BiopharmaWatch
en
2026-08-31T20:15:00.000Z
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
https://www.biopharmawatch.com/news/ENOV/enovis-participate-2026-wells-fargo-healthcare-conference
BiopharmaWatch
en
2026-08-31T20:15:00.000Z
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
https://www.biopharmawatch.com/news/SIBN/si-bone-presents-morgan-stanley-healthcare-conference-2026
BiopharmaWatch
en
2026-08-31T20:09:00.000Z
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
https://www.biopharmawatch.com/news/ALGN/quentin-blackford-joins-align-technology-board
BiopharmaWatch
en
2026-08-31T20:08:00.000Z
Quentin Blackford to Join Align Technology Board of Directors
https://www.biopharmawatch.com/news/VIR/vir-biotechnology-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-08-31T20:05:00.000Z
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/NPCE/neuropace-participate-wells-fargo-healthcare-conference
BiopharmaWatch
en
2026-08-31T20:05:00.000Z
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-hc-wainwright-conference
BiopharmaWatch
en
2026-08-31T20:05:00.000Z
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
https://www.biopharmawatch.com/news/KYNB/kyntra-bio-reduces-royalty-financing-obligation
BiopharmaWatch
en
2026-08-31T20:05:00.000Z
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
https://www.biopharmawatch.com/news/IVA/inventiva-appoints-chris-benecchi-coo
BiopharmaWatch
en
2026-08-31T20:05:00.000Z
Inventiva nomme Chris Benecchi au poste de Chief Operating Officer
https://www.biopharmawatch.com/news/IVA/inventiva-appoints-chris-benecchi-coo
BiopharmaWatch
en
2026-08-31T20:05:00.000Z
Inventiva Appoints Chris Benecchi as Chief Operating Officer
https://www.biopharmawatch.com/news/SYK/stryker-acquires-zurimed-enhance-shoulder-offering
BiopharmaWatch
en
2026-08-31T20:05:00.000Z
Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-labs-sci-210-autism-trial-enrollment
BiopharmaWatch
en
2026-08-31T20:03:00.000Z
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
https://www.biopharmawatch.com/news/PMVP/pmv-pharma-proposed-public-offering-securities
BiopharmaWatch
en
2026-08-31T20:02:00.000Z
PMV Pharma Announces Proposed Public Offering of Securities
https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-investor-conferences-2026
BiopharmaWatch
en
2026-08-31T20:01:00.000Z
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
https://www.biopharmawatch.com/news/GRAL/grail-presentation-morgan-stanley-healthcare-conference
BiopharmaWatch
en
2026-08-31T20:01:00.000Z
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-q1-2027-results
BiopharmaWatch
en
2026-08-31T20:01:00.000Z
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14
https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-updated-rezatapopt-ovarian-cancer-data
BiopharmaWatch
en
2026-08-31T20:01:00.000Z
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
https://www.biopharmawatch.com/news/WAT/wellinks-appoints-agwunobi-waters-board-directors
BiopharmaWatch
en
2026-08-31T19:51:00.000Z
Wellinks Appoints Andrew Agwunobi and Mike Waters to Board of Directors and Expands Management Team
https://www.biopharmawatch.com/news/LOBE/lobe-sciences-private-placement-august-2026
BiopharmaWatch
en
2026-08-31T19:00:00.000Z
Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-medicines
BiopharmaWatch
en
2026-08-31T19:00:00.000Z
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
https://www.biopharmawatch.com/news/HIMS/hims-enters-australia-asia-pacific-expansion
BiopharmaWatch
en
2026-08-31T19:00:00.000Z
Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market
https://www.biopharmawatch.com/news/EXEL/exelixis-patent-litigation-update-msn-laboratories
BiopharmaWatch
en
2026-08-31T18:30:00.000Z
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-participate-morgan-stanley-conference
BiopharmaWatch
en
2026-08-31T18:00:00.000Z
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-her2-cancer
BiopharmaWatch
en
2026-08-31T17:25:00.000Z
BeOne Medicines gibt neue Überlebensdaten aus Phase-3-Studien bekannt, die den Nutzen von ZIIHERA-haltigen Therapien bei HER2-positivem gastroösophagealem Krebs in der Erstlinienbehandlung untermauern
https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-her2-cancer-results
BiopharmaWatch
en
2026-08-31T17:25:00.000Z
Samenvatting: BeOne Medicines kondigt nieuwe overlevingsgegevens uit Fase 3-studie aan die het voordeel bevestigen van behandelregimes met ZIIHERA bij eerstelijnsbehandeling van HER2-positieve gastro-oesofageale kanker
https://www.biopharmawatch.com/news/TNON/wallachbeth-capital-closes-tenon-medical-private-placement
BiopharmaWatch
en
2026-08-31T16:30:00.000Z
WallachBeth Capital Announces Closing of Tenon Medical
https://www.biopharmawatch.com/news/BTMD/biotecanada-2026-gold-leaf-award-winners
BiopharmaWatch
en
2026-08-31T14:49:00.000Z
BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology Ecosystem
https://www.biopharmawatch.com/news/HLF/herbalife-reaffirms-guidance-2026
BiopharmaWatch
en
2026-08-31T13:54:00.000Z
Herbalife Reaffirms Third Quarter and Full Year 2026 Guidance